|1.||Seth, Rakhi: 3 articles (09/2014 - 01/2014)|
|2.||Buchbinder, Rachelle: 3 articles (09/2014 - 01/2014)|
|3.||Edwards, Christopher J: 3 articles (09/2014 - 01/2014)|
|4.||Bombardier, Claire: 3 articles (09/2014 - 01/2014)|
|5.||van der Heijde, Désirée M: 2 articles (09/2014 - 09/2014)|
|6.||Falzon, Louise: 2 articles (09/2014 - 09/2014)|
|7.||Kydd, Alison S R: 2 articles (01/2014 - 01/2014)|
|8.||Gravatt, Lance: 2 articles (09/2013 - 09/2013)|
|9.||Tadjuidje, Emmanuel: 2 articles (01/2013 - 01/2012)|
|10.||McDonald, Matthew G: 2 articles (01/2013 - 12/2007)|
09/01/2007 - "A prospective, open study was carried out in a cohort of 51 gout patients who discontinued benzbromarone therapy because of market withdrawal. "
03/01/2014 - "Prospective CYP2C9 genotyping of Caucasian gout patients may be warranted for benzbromarone, whereas the low frequencies of CYP2C9 PM alleles in Polynesians suggests that the CYP2C9 polymorphism may be of little or no relevance to benzbromarone prescribing in this population."
03/01/2014 - "Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone."
09/13/2013 - "Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?"
01/01/2013 - "Benzbromarone, a known anti-gout agent, was previously identified as an inhibitor of EYA with anti-angiogenic properties. "
01/01/2015 - "Second, the intracellular antioxidant activity of benzbromarone in hyperuricemia was evaluated using endothelial cells. "
01/01/2015 - "Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment."
07/01/2013 - "Its effects were similar with that of benzbromarone, but with no significant effect on XOD and urinary volume of chronic hyperuricemia rats. "
12/01/2011 - "These results suggest that benzbromarone is applicable to the management of hyperuricemia associated with renal impairment."
09/01/2011 - "99 patients with hyperuricemia were randomly assigned to the XCR group, the Benzbromarone group, and the blank control group. "
|3.||Renal Insufficiency (Renal Failure)
04/01/1978 - "[Hypouricemic effect of benzbromarone especially in kidney failure]."
02/01/2001 - "If available (as in Europe, South Africa, and Japan), benzbromarone may be tried in patients with gout and mild-to-moderate renal insufficiency. "
10/01/2006 - "The uricosuric benzbromarone is more effective than allopurinol (ES = 1.50 (0.76 to 2.24)) and can be used in patients with mild to moderate renal insufficiency but may be hepatotoxic. "
11/01/2004 - "Patients with renal failure precluding the use of effective allopurinol dosages are good candidates for benzbromarone therapy. "
04/01/1999 - "At present, there is no study available comparing the efficacy of the most widely used agent, allopurinol, and the uricosuric benzbromarone for the control of hyperuricemia in patients with renal insufficiency. "
|4.||Heart Diseases (Heart Disease)
09/01/1994 - "Allopurinol and benzbromarone together were partially effective treatments for hyperuricemia in this patient with cyanotic congenital heart disease."
12/01/1999 - "Warfarin enantiomers and benzbromarone in serum, 7-hydroxywarfarin in urine, and serum unbound fractions of warfarin enantiomers were measured in patients with heart disease given warfarin with (n = 13) or without (n = 18) oral benzbromarone (50 mg/d). "
|2.||Uric Acid (Urate)
|3.||benzbromarone drug combination allopurinol
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)